{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:57:43Z","timestamp":1771689463759,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"DOI":"10.1002\/ejhf.3245","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:39:00Z","timestamp":1713242340000},"page":"948-951","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Changing Landscape of Heart Failure Treatment in Transthyretin Amyloid Cardiomyopathy: Is the Time Ripe for Clinical Use of Sodium\u2013Glucose Cotransporter 2 Inhibitors?"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0825","authenticated-orcid":false,"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London ,","place":["UK"]},{"name":"Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]},{"name":"European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart , Trieste ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2026010913075394800_ejhf3245-bib-0001","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026010913075394800_ejhf3245-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913075394800_ejhf3245-bib-0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026010913075394800_ejhf3245-bib-0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075394800_ejhf3245-bib-0006","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913075394800_ejhf3245-bib-0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913075394800_ejhf3245-bib-0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913075394800_ejhf3245-bib-0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: Early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033094","article-title":"Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis","volume":"13","author":"Ioannou","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026010913075394800_ejhf3245-bib-0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026010913075394800_ejhf3245-bib-0014","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"key":"2026010913075394800_ejhf3245-bib-0015","first-page":"e303","article-title":"Sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy","volume":"148","author":"Porcari","year":"2023","journal-title":"Circulation"},{"key":"2026010913075394800_ejhf3245-bib-0016","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026010913075394800_ejhf3245-bib-0017","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913075394800_ejhf3245-bib-0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026010913075394800_ejhf3245-bib-0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: Results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913075394800_ejhf3245-bib-0021","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/948\/65514522\/eurjhf_26_4_948.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/948\/65514522\/eurjhf_26_4_948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:47Z","timestamp":1767982187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/4\/948\/8328880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3245","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2024-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}